Podyacheva E, Kushnareva E, Karpov A, Toropova Y
Front Pharmacol. 2021; 12:670479.
PMID: 34149423
PMC: 8209419.
DOI: 10.3389/fphar.2021.670479.
Hewitson T, Holt S, Smith E
Front Immunol. 2015; 6:465.
PMID: 26441970
PMC: 4585255.
DOI: 10.3389/fimmu.2015.00465.
Noguchi C, Miyata H, Sato Y, Iwaki Y, Okuyama S
J Toxicol Pathol. 2012; 24(1):41-8.
PMID: 22272043
PMC: 3234621.
DOI: 10.1293/tox.24.41.
Malarkodi K, Balachandar A, Varlakshmi P
Mol Cell Biochem. 2003; 247(1-2):139-45.
PMID: 12841641
DOI: 10.1023/a:1024175325850.
Singal P, Li T, Kumar D, Danelisen I, Iliskovic N
Mol Cell Biochem. 2000; 207(1-2):77-86.
PMID: 10888230
DOI: 10.1023/a:1007094214460.
Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.
Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T
Invest New Drugs. 1998; 16(2):121-8.
PMID: 9848575
DOI: 10.1023/a:1006088907271.
Rodent models of cardiopulmonary disease: their potential applicability in studies of air pollutant susceptibility.
Kodavanti U, Costa D, Bromberg P
Environ Health Perspect. 1998; 106 Suppl 1:111-30.
PMID: 9539009
PMC: 1533271.
DOI: 10.1289/ehp.98106s1111.
Lipid lowering: an important factor in preventing adriamycin-induced heart failure.
Iliskovic N, Singal P
Am J Pathol. 1997; 150(2):727-34.
PMID: 9033285
PMC: 1858278.
Doxorubicin-induced cardiac neurotoxicity: study with iodine 123-labeled metaiodobenzylguanidine scintigraphy.
Lekakis J, Prassopoulos V, Athanassiadis P, KOSTAMIS P, MOULOPOULOS S
J Nucl Cardiol. 1996; 3(1):37-41.
PMID: 8799226
DOI: 10.1016/s1071-3581(96)90022-7.
Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Herman E, Zhang J, Ferrans V
Cancer Chemother Pharmacol. 1994; 35(2):93-100.
PMID: 7987999
DOI: 10.1007/BF00686629.
The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat.
van de Vrie W, Jonker A, Marquet R, Eggermont A
J Cancer Res Clin Oncol. 1994; 120(9):533-8.
PMID: 7913932
DOI: 10.1007/BF01221030.
Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants.
Van Vleet J, Ferrans V, Weirich W
Am J Pathol. 1980; 99(1):13-42.
PMID: 7361854
PMC: 1903483.
Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.
Forssen E, Tokes Z
Proc Natl Acad Sci U S A. 1981; 78(3):1873-7.
PMID: 6940195
PMC: 319237.
DOI: 10.1073/pnas.78.3.1873.
Lysosomal alterations in heart and liver of mice treated with doxorubicin.
Gebbia N, Leto G, Gagliano M, Tumminello F, Rausa L
Cancer Chemother Pharmacol. 1985; 15(1):26-30.
PMID: 4006046
DOI: 10.1007/BF00257289.
Systemic influence of intravesical chemotherapy with verapamil.
Simpson W, Tseng M, Harty J
Urol Res. 1985; 13(1):23-6.
PMID: 3922100
DOI: 10.1007/BF00571752.
Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
Herman E, Ferrans V, BHAT H, Witiak D
Cancer Chemother Pharmacol. 1987; 19(4):277-81.
PMID: 3594714
DOI: 10.1007/BF00261472.
Effects of chronic administration of doxorubicin on plasma levels of prostaglandins, thromboxane B2, and fatty acids in rats.
Robison T, Giri S
Cancer Chemother Pharmacol. 1987; 19(3):213-20.
PMID: 3581414
DOI: 10.1007/BF00252975.
Myocardial diseases of animals.
Van Vleet J, Ferrans V
Am J Pathol. 1986; 124(1):98-178.
PMID: 3524254
PMC: 1888177.
Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity.
Miyagawa M, Tanada S, Hamamoto K
Eur J Nucl Med. 1991; 18(5):332-8.
PMID: 1834467
DOI: 10.1007/BF02285461.
Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine.
Al-Harbi M, Al-Shabanah O, Al-Bekairi A, Osman A, Tawfik H
Cancer Chemother Pharmacol. 1992; 31(3):200-4.
PMID: 1464156
DOI: 10.1007/BF00685548.
